Key TakeawaysGilead Sciences has entered an agreement to purchase German biotech firm Tubulis GmbH in a deal valued at up to $5 billion.The biopharmaceutical giant will pay $3.15 billion upfront, with an additional $1.85 billion contingent on developmental milestones.This acquisition strengthens Gilead’s antibody-drug conjugate (ADC) platform, with focus areas including ovarian and non-small cell lung cancers.RBC Capital Markets increased its GILD price target from $118 to $123, maintaining a Sector Perform rating on the stock.Analysts at RBC project Yeztugo could surpass Q1 estimates by approximately $180 million, though sustainability concerns remain.Multiple Wall Street firms including Cantor Fitzgerald, UBS, and Deutsche Bank maintain bullish positions with targets reaching $155.Gilead Sciences (GILD) is making a significant move to bolster its oncology capabilities by acquiring Munich-headquartered Tubulis GmbH in an all-cash transaction worth as much as $5 billion.Gilead Sciences agrees to buy private German biotech Tubulis in a deal worth up to $5 billion as it looks to boost its portfolio in a hot new area of cancer drug development, sources say https://t.co/KRZYp5EQv0— Bloomberg (@business) April 7, 2026The pharmaceutical company will deliver an initial payment of $3.15 billion, supplemented by potential milestone-based payments totaling $1.85 billion. Financing will come from existing cash reserves and newly issued senior unsecured notes, with the transaction anticipated to close during the second quarter of 2026.Tubulis specializes in developing antibody-drug conjugates, an innovative cancer treatment approach that delivers chemotherapy agents directly to malignant cells while minimizing damage to surrounding healthy tissue. The company’s most advanced candidate, TUB-040, is undergoing Phase 1b/2 clinical testing for platinum-resistant ovarian cancer and non-small cell lung cancer.Gilead Sciences, Inc., GILDChief Executive Daniel O’Day characterized the acquisition as creating what may be the most robust and varied pipeline in Gilead’s corporate history.Shares retreated approximately 1.37% Tuesday following the announcement, a standard market response when companies commit substantial upfront capital to acquisitions.RBC Upgrades Target While Maintaining Cautious OutlookRBC Capital Markets increased its GILD price objective to $123 from the previous $118 level, though analysts maintained their Sector Perform rating—effectively a neutral recommendation. The firm highlighted encouraging early performance metrics for Yeztugo, one of Gilead’s recent launches, based on third-party prescription tracking data.According to RBC’s analysis, Yeztugo could exceed Q1 consensus projections by approximately $180 million, significantly outperforming the Street’s $141 million estimate. Should this materialize, it would represent a substantial positive surprise.However, RBC expressed measured caution regarding forward projections. Analysts observed that institutional investor expectations for fiscal 2026 already incorporate revenue of roughly $1 billion. Should patient adherence rates or market penetration fail to meet expectations, more aggressive peak sales forecasts could require downward revision.Current adherence metrics stand at approximately 70% based on RBC’s channel checks—a respectable figure, though one that provides limited cushion for deterioration.RBC also identified potential headwinds in other segments. The firm’s HIV franchise revenue projection of $4.8 billion falls short of the $4.9 billion consensus, while Veklury is forecast to generate $141 million against Street expectations of $216 million.Gilead’s first quarter financial results are scheduled for release on April 23.Wall Street Analysts Maintain Optimistic StanceSeveral investment banks continue expressing confidence in Gilead’s trajectory. Cantor Fitzgerald reaffirmed its Overweight recommendation with a $155 price objective, highlighting robust prescription momentum throughout Gilead’s HIV product portfolio.UBS similarly sustained its Buy rating, noting a remarkable 56% sequential increase in Yeztugo revenues during February. Deutsche Bank also maintained its Buy rating and $155 target, forecasting first quarter Yeztugo sales of approximately $118 million.In a separate development, Gilead announced an extension to the tender offer deadline for Arcellx common shares through April 24, 2026. The offer provides $115.00 per share in cash along with contingent value rights linked to future commercial performance.As the April 23 earnings date approaches, investor focus will center on whether Yeztugo’s promising early trajectory delivers a meaningful consensus beat.The post Gilead Sciences (GILD) Seals $5B Tubulis Deal to Strengthen Oncology Portfolio appeared first on Blockonomi.